FDA broadens reach of GE HealthCare's amyloid imaging agent Vizamyl in Alzheimer's diagnostics
The imaging agent can be used to deliver quantitative assessments such as calculations of amyloid prevalence through FDA-authorized software.
The imaging agent can be used to deliver quantitative assessments such as calculations of amyloid prevalence through FDA-authorized software.
